US Pharma MarketingASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 lung cancer market, Dizal Pharma has data showing its small molecule drug may have what it takes to challenge Johnson & Johnson’s antibody in the first-line setting. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation…
About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 lung cancer market, Dizal Pharma has data showing its small molecule drug may have what it takes to challenge Johnson & Johnson’s antibody in the first-line setting.
Source: FiercePharma